NCT04026269

Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen

Clinical Efficacy of MOAP Regimen for Relapsed/Refractory Classical Hodgkin's Lymphoma as a Rescue Therapy After Ineffective Treatment of Additional Low-dose Decitabine to Anti-PD-1 Antibody Camrelizumab

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Han weidong · Academic / Other
• Sex: All
• Age: 13 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The DP regimen, low-dose decitabine combined with SHR-1210, is the new treatment for relapsed or refractory classical Hodgkin's Lymphoma. Though the CR rate of this regimen is impressively high, which is verified more than 70% in our I/II phase study, there are also lots of patients cannot benefit from this treatment. On top of that, as the increasing utilization of mono-therapy or combination treatment with the immune checkpoint blockade (ICB), the adverse reactions associated with immunotherapy make it unavailable in parts of patients. The application of MOAP regimen to patients, who have a progressive disease after DP regimen, can bring high CR rate. MOAP can be the a rescue treatment for cHL resisted to DP treatment.

Conditions

• Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	MOAP	the new chemotherapy regimen for r/r cHL

Timeline

• Start date: 2019-07-30
• Primary completion: 2020-12-31
• Completion: 2020-12-31
• First posted: 2019-07-19
• Last updated: 2019-07-19

Locations

1 site across 1 country: China